UPCC 28218: A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Brief description of study

This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years of therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal cancer
  • Age: - 99 Years
  • Gender: All
Updated on 29 Jan 2020. Study ID: 831705

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center